Shawnte Mitchell

CIK: 0001749432

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OLMA

Olema Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

OLMA
Olema Pharmaceuticals, Inc.
Mar 4, 2026
Sale(S)
Direct
24.8K shares at avg. $24.25$601K
OLMA
Olema Pharmaceuticals, Inc.
Mar 4, 2026
Sale(S)
Direct
233 shares at avg. $24.69$6K
OLMA
Olema Pharmaceuticals, Inc.
Mar 4, 2026
Exercise(M)
Direct
25K shares at avg. $4.37$109K
OLMA
Olema Pharmaceuticals, Inc.
Mar 3, 2026
Exercise(M)
Direct
15K shares at avg. $4.37$66K
OLMA
Olema Pharmaceuticals, Inc.
Mar 3, 2026
Sale(S)
Direct
15K shares at avg. $23.01$345K
OLMA
Olema Pharmaceuticals, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
220K shares-
OLMA
Olema Pharmaceuticals, Inc.
Feb 2, 2026
Award(A)
Performance Stock Options (Right to Buy)
Direct
56.3K shares-
OLMA
Olema Pharmaceuticals, Inc.
Feb 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
450K shares-

		Type	Shares	Price		Ownership
Mar 4, 2026	OLMA Olema Pharmaceuticals, Inc.	Sale(S)	24,767	$24.25	$600,600	Direct
Mar 4, 2026	OLMA Olema Pharmaceuticals, Inc.	Sale(S)	233	$24.69	$5,753	Direct
Mar 4, 2026	OLMA Olema Pharmaceuticals, Inc.	Exercise(M)	25,000	$4.37	$109,250	Direct
Mar 3, 2026	OLMA Olema Pharmaceuticals, Inc.	Exercise(M)	15,000	$4.37	$65,550	Direct
Mar 3, 2026	OLMA Olema Pharmaceuticals, Inc.	Sale(S)	15,000	$23.01	$345,150	Direct
Feb 2, 2026	OLMA Olema Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	220,000	-	-	Direct
Feb 2, 2026	OLMA Olema Pharmaceuticals, Inc.	Award(A) Performance Stock Options (Right to Buy)	56,250	-	-	Direct
Feb 28, 2025	OLMA Olema Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	450,000	-	-	Direct

1-8 of 8 transactions

About Mitchell Shawnte

Mitchell Shawnte (SEC CIK 0001749432) files insider reports with the SEC as CHIEF LEGAL OFFICER of Olema Pharmaceuticals, Inc. (OLMA).

Signal8 holds 4 ownership filings by Mitchell Shawnte (1 Form 3, 3 Form 4), filed between Feb 28, 2025 and Mar 5, 2026. Those filings report 8 transactions, from Feb 28, 2025 to Mar 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mitchell Shawnte's filings is in SAN FRANCISCO, CA.

Recent filings by Mitchell Shawnte

Mar 4, 2026: Open-market sales of OLMA shares (2 lines, Form 4, code S).
Mar 4, 2026: Option exercise of OLMA shares (Form 4, code M).
Mar 3, 2026: Option exercise of OLMA shares (Form 4, code M).
Mar 3, 2026: Open-market sale of OLMA shares (Form 4, code S).
Feb 2, 2026: Grants or awards of OLMA derivative securities (2 lines, Form 4, code A).

Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)

O'Byrne Jason, CHIEF FINANCIAL OFFICER
Harmon Cyrus, Director
BVF PARTNERS L P/IL, Director
BUTITTA CYNTHIA M, Director
Garland J. Scott, Director
Hrustanovic Gorjan, Director

How to read Form 4 transaction codes